CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Maravai LifeSciences Q3 results beat estimates on mRNA products; raises FY outlook

By Reuters News


Overview

  • US life science reagents provider's Q3 revenue rose 10%, beating analyst expectations

  • Adjusted EBITDA for Q3 beat consensus, driven by mRNA and GMP consumables demand

  • Company raised full-year 2026 revenue and adjusted EBITDA guidance


Outlook

  • Maravai raises full-year 2026 revenue guidance to $212 mln-$216 mln, up from $205 mln-$215 mln

  • Company lifts 2026 adjusted EBITDA guidance to $40 mln-$42 mln, previously $33 mln-$35 mln

  • Maravai expects continued demand for Discovery mRNA and GMP consumables to drive growth


Result Drivers

  • MRNA PRODUCTS - Co said 28% year-over-year growth in mRNA products drove TriLink segment revenue

  • GMP CONSUMABLES DEMAND - Increased demand for Discovery mRNA and GMP consumables contributed to TriLink revenue growth

  • CYGNUS SEGMENT GROWTH - Cygnus revenue rose 7.5% year-over-year, driven by demand for Host Cell Protein and ELISA kits


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$45.85 mln

$43.57 mln (9 Analysts)

Q3 Net Loss

$24 mln

Q3 Adjusted EBITDA

Beat

$5.82 mln

$512,860 (7 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Maravai Lifesciences Holdings, Inc. is $8.00, about 7.4% above its November 3 closing price of $7.45


Reuters Recommended Reads

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 4 - Novo Nordisk Q3 adjusted profit, sales jump on GLP-1 demand; raises outlook

  • Nov 3 - Pfizer Q3 revenue beats estimates on new launches; raises guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.